Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting Immunocore (Nasdaq: IMCR) will present the five-year overall survival (OS) results from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive metastatic uveal melanoma at AACR 2026.The oral presentation is scheduled for Sunday, 19 April 2026, 3:00–5:00 p.m. PT; a company release will follow with the full five-year OS data and additional analyses including subsequent treatments, treatment beyond progression, and prognostic factors.

#IMCR Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

www.stocktitan.net/news/IMCR/immunocore-wil...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma

#IMCR Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/IMCR/immunocore-ann...

‘Jihad’ being deliberately exploited: IMCR chief Mohammad Adeeb backs Madani’s remarks (IANS Interview) New Delhi, Dec 13 (SocialNews.XYZ) Indian Muslims for Civil Rights (IMCR) Chairman and former MP Mohammad Adeeb on Saturday said that the concept of jihad is being "deliberately exploited" by some individuals, while drawing parallels with the teachings of the Mahabharata. His remarks come against the backdrop of a political firestorm over Jamiat Ulama-e-Hind (JUH) president Maulana Mahmood Madani's recent statement that the concept of 'jihad' is significant not only for Muslims but for the entire nation, adding that it should be included in school education so that children understand its meaning and purpose.

'Jihad' being deliberately exploited: IMCR chief Mohammad Adeeb backs Madani's remarks (IANS Interview) #Jihad #IMCR #MohammadAdeeb #Madanis #IANSInterview #socialnewsxyz

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting Immunocore (Nasdaq: IMCR) presented Phase 1 single‑ascending‑dose data for IMC-I109V at AASLD The Liver Meeting on November 7, 2025. The bispecific TCR candidate showed a manageable safety profile and pharmacodynamic activity consistent with its mechanism, including dose‑dependent reductions in HBsAg at doses ≥ 7 mcg, with HBsAg nadirs typically by day 8. Four participants met the predefined ≥ 0.2 log10 HBsAg reduction threshold. Treatment‑related adverse events were mostly transient; one Grade 2 cytokine release syndrome at 20 mcg resolved with treatment.The company plans further evaluation in multiple‑dose regimens.

#IMCR Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

www.stocktitan.net/news/IMCR/immunocore-pre...

Immunocore reports second quarter financial results and provides a business update Immunocore (NASDAQ:IMCR) reported strong Q2 2025 financial results, with KIMMTRAK net revenues reaching $98.0 million, representing a 30% year-over-year growth. The company achieved significant market expansion with KIMMTRAK now approved in 39 countries and launched in 28 countries globally.Key highlights include 15% growth in US sales and 71% growth in Europe and international regions. The company maintains a strong financial position with $883 million in cash and equivalents. R&D expenses increased to $69.0 million, reflecting investments in autoimmune programs and Phase 3 trials.Clinical progress remains on track with the Phase 3 TEBE-AM trial expected to complete enrollment in 1H 2026, and dose selection for PRISM-MEL-301 Phase 3 trial anticipated in 2H 2025. The company reported a reduced net loss of $10.3 million compared to $11.6 million in the same period last year.

#IMCR Immunocore reports second quarter financial results and provides a business update

www.stocktitan.net/news/IMCR/immunocore-rep...

Solid Runner Recap, 3 New Chances **Thursday Recap:** Things went very well for us on Thursday, after we hashed out four possible options targets in our premarket report**.** We have enjoyed some really nice activity off of our options ideas this week, and yesterday was no exception to that. All of our ideas panned out pretty well. We had the **SPY 05/29 $591-593 Calls** , the **BURL Weekly $255-257.50 Calls** , the **VEEV Weekly $260-270 Calls** , and the **NVDA Weekly $140-142 Calls** on our daily watchlist and these were the numbers they put up: **SPY 05/29 $591-593 Calls $591:** 1.67-2.92 (+75%) **$592:** 1.41-2.44 (+73%) **$593:** 1.16-2.03 (+75%) _____** ** **BURL Weekly $255-257.50 Calls $255:** .05-.29 (+480%) **$257.50:** .06-.22 (+266%) _____ **VEEV Weekly $260-270 Calls** **$260:** 12.25-28.00 (+129%) **$270:** 9.61-19.55 (+103%) _____ **NVDA Weekly $140-142 Calls** **$140:** 1.78-2.99 (+68%) **$141:** .50-.85 (+70%) **$142:** .31-.55 (+77%) * * * **Fresh Options Ideas: MRVL Weekly $63-61 Puts GAP Weekly $25-24 Puts COO 06/20 $75-70 Puts** _*Trading options contracts on their day of expiration should only be attempted by experienced traders_ * * * **Sharplink Gaming Ltd. (NASDAQ:SBET) – Recap:** We first tagged SBET on Tuesday morning, and on that day we saw a low of 27.23 in the stock, which, as of this morning has traded for as high as 121.00. That’s an amazing increase of 344% * * * **Extended Watchlist: ECDA, BURU, AI, LZMH, IMCR, MRUS, EVKRF, TWOH**

Solid Runner Recap, 3 New Chances Thursday Recap: Things went very well for us on Thursday, after...

bluehorseshoestocks.com/solid-runner-recap-3-new...

#Daily #Report #AI #BURL #BURU #COO #ECDA #EVKRF #GAP #IMCR #LZMH

Result Details

Immunocore reports first quarter financial results and provides a business update Immunocore (IMCR) reported strong Q1 2025 financial results, with KIMMTRAK net revenues reaching $93.9 million, up 33% year-over-year. The company achieved net income of $5.0 million compared to a $24.4 million loss in Q1 2024, with earnings per share of $0.10. KIMMTRAK is now approved in 39 countries and launched in 26 markets globally. The company maintains a strong financial position with $837 million in cash and equivalents. Key pipeline developments include progress in Phase 3 trials: TEBE-AM trial enrollment completion expected in 1H 2026, and dose selection for PRISM-MEL-301 trial anticipated in 2H 2025. The company also presented initial multiple ascending dose data for their HIV functional cure candidate at CROI 2025.

#IMCR Immunocore reports first quarter financial results and provides a business update

www.stocktitan.net/news/IMCR/immunocore-rep...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 Immunocore (NASDAQ: IMCR) has presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional HIV cure candidate. The study included 16 HIV-positive participants across three dose cohorts (60 mcg, 120 mcg, and 300 mcg).Key findings show that IMC-M113V was well-tolerated with no serious adverse events. The 300 mcg cohort showed promising results, with 2 out of 5 patients demonstrating viral control. Notably, these patients maintained viral loads around 200 c/mL at week 8, significantly better than the historical rate of 5%.The trial revealed dose-dependent viral control after antiretroviral treatment interruption, with some patients showing reduced CD4+ T cell-associated HIV Gag RNA, indicating a reduction in active virus reservoir. Two patients remained off antiretroviral treatment for the entire 12-week interruption period, with one patient showing viral reduction to

#IMCR Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

www.stocktitan.net/news/IMCR/immunocore-pre...

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.Key developments include:KIMMTRAK now approved in 39 countries and launched in 24First patient randomized in Phase 3 PRISM-MEL-301 trialInitiated Phase 1/2 trial of IMC-R117C for colorectal cancersStrong cash position of $820.4M as of December 31, 2024Repaid $50M Pharmakon loan in November 2024

#IMCR Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

www.stocktitan.net/news/IMCR/immunocore-rep...

Immunocore Unveils Ambitious 2025 Strategy: Global KIMMTRAK Expansion, $820M War Chest Immunocore advances melanoma franchise with KIMMTRAK now in 23 countries, three Phase 3 trials underway, and new autoimmune disease programs launching in 2025-2026.

#IMCR Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/IMCR/immunocore-ann...

"Anti-Wormhole" in Incremental Mass Rewritten style.

#incrementalmassrewritten #imr #imcr

Immunocore Advances Cancer Treatment Pipeline: Launches Phase 1 Trial for Enhanced PRAME-Targeting Therapy Immunocore initiates clinical trial for IMC-P115C, an innovative long-acting cancer therapy targeting PRAME. Built on proven technology with improved patient convenience.

#IMCR Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

www.stocktitan.net/news/IMCR/immunocore-ann...

Immunocore Launches Groundbreaking PIWIL1 Cancer Trial: First-Ever Immunotherapy Targeting Colorectal Cancer Immunocore initiates Phase 1/2 trial for novel immunotherapy IMC-R117C, first-ever targeting PIWIL1 in colorectal cancer, potentially benefiting 20,000 patients globally.

#IMCR Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

www.stocktitan.net/news/IMCR/immunocore-ann...

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma Immunocore (NASDAQ: IMCR) and EORTC have initiated the first Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), enrolling their first patient. The trial aims to evaluate if tebentafusp can prevent or delay relapse in high-risk uveal melanoma patients after primary treatment, compared to observation.The open-label, international, multicenter trial will enroll 290 HLA-A*02:01-positive patients who have undergone surgery or radiotherapy. Participants will be randomized 1:1 to receive either tebentafusp for six months or observation. The study will assess overall survival, safety, tolerability, and explore ctDNA as a marker of residual disease.Tebentafusp (KIMMTRAK®) is currently approved in 38 countries for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

#IMCR EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

#news #investing #stocks

www.stocktitan.net/news/IMCR/eortc-and-immu...